Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Q32 Bio (QTTB) EBIT (2018 - 2025)

Historic EBIT for Q32 Bio (QTTB) over the last 8 years, with Q3 2025 value amounting to -$7.6 million.

  • Q32 Bio's EBIT rose 5972.68% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year increase of 4378.5%. This contributed to the annual value of -$66.1 million for FY2024, which is 3698.48% down from last year.
  • Q32 Bio's EBIT amounted to -$7.6 million in Q3 2025, which was up 5972.68% from -$9.2 million recorded in Q2 2025.
  • Over the past 5 years, Q32 Bio's EBIT peaked at -$1.1 million during Q1 2021, and registered a low of -$37.6 million during Q1 2022.
  • Its 5-year average for EBIT is -$19.6 million, with a median of -$17.9 million in 2024.
  • In the last 5 years, Q32 Bio's EBIT surged by 9695.55% in 2021 and then tumbled by 328595.86% in 2022.
  • Quarter analysis of 5 years shows Q32 Bio's EBIT stood at -$33.6 million in 2021, then decreased by 2.58% to -$34.5 million in 2022, then increased by 25.18% to -$25.8 million in 2023, then skyrocketed by 43.72% to -$14.5 million in 2024, then surged by 47.84% to -$7.6 million in 2025.
  • Its EBIT was -$7.6 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$12.2 million in Q1 2025.